Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Dova Pharmaceuticals
|
| gptkbp:alsoKnownAs |
gptkb:Sobi
|
| gptkbp:CEO |
gptkb:Guido_Oelkers
|
| gptkbp:country |
gptkb:Sweden
|
| gptkbp:focusesOn |
immunology
hematology rare diseases |
| gptkbp:founded |
2001
|
| gptkbp:foundedBy |
merger of Swedish Orphan International and Biovitrum
|
| gptkbp:headquartersLocation |
gptkb:Stockholm,_Sweden
|
| https://www.w3.org/2000/01/rdf-schema#label |
Swedish Orphan Biovitrum AB
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:ISIN |
SE0000872095
|
| gptkbp:listedOn |
gptkb:Nasdaq_Stockholm
|
| gptkbp:netIncome |
SEK 2.6 billion (2022)
|
| gptkbp:numberOfEmployees |
~1,500
|
| gptkbp:parentCompany |
Advent International (majority owner as of 2023)
|
| gptkbp:products |
gptkb:Alprolix
gptkb:Elocta gptkb:Kineret gptkb:Orfadin Gamifant |
| gptkbp:revenue |
SEK 18.8 billion (2022)
|
| gptkbp:stockSymbol |
gptkb:SOBI
|
| gptkbp:website |
https://www.sobi.com/
|
| gptkbp:bfsParent |
gptkb:Sobi
|
| gptkbp:bfsLayer |
7
|